(E)-1-(2-methoxyphenyl)-3-(4-nitrophenyl)prop-2-en-1-one | 42067-83-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: (E)-1-(2-methoxyphenyl)-3-(4-nitrophenyl)prop-2-en-1-one
• 英文别名: 3-(2-methoxyphenyl)-1-(4-nitrophenyl)-propenone
• CAS: 42067-83-4
• 化学式: C₁₆H₁₃NO₄
• 分子量: 283.284
• InChiKey: WVFQHFZZAHVONO-DHZHZOJOSA-N

物化性质

• 沸点：
  447.8±45.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  72.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (E)-1-(2-methoxyphenyl)-3-(4-nitrophenyl)prop-2-en-1-one 在 三乙胺 、 lithium chloride 作用下， 以 N,N-二甲基甲酰胺 、 苯 为溶剂， 反应 12.0h， 生成 (2-Methoxy-phenyl)-[4-(4-nitro-phenyl)-2,5-diphenyl-2H-pyrazol-3-yl]-methanone
  参考文献：
  名称：

  M'Sadek, Moncef; Rammah, Mohammed; Schmitt, Gerard, Bulletin des Societes Chimiques Belges, 1992, vol. 101, # 4, p. 323 - 328

  摘要：

  DOI：
• 作为产物：
  描述：

  邻甲氧基苯甲醛 、 对硝基苯乙酮 在 montmorillonite KSF 作用下， 反应 1.0h， 以84.4%的产率得到(E)-1-(2-methoxyphenyl)-3-(4-nitrophenyl)prop-2-en-1-one
  参考文献：
  名称：

  Solvent free synthesis of 1,3-diaryl-2-propenones catalyzed by commercial acid-clays under ultrasound irradiation

  摘要：

  This paper presents a novel solvent free method of synthesis of trans-chalcones. The method was based on ultrasound irradiation of the reagents (aryl methyl ketones and aryl aldehydes) in presence of commercial acid-montmorillonites as catalysts. The trans-chalcones were synthesized in high yields (85-95%) and excellent selectivity in a short reaction time. (C) 2009 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.ultsonch.2009.06.008

文献信息

• [EN] ALLOSTERIC INHIBITORS OF ATYPICAL PROTEIN KINASES C<br/>[FR] INHIBITEURS ALLOSTÉRIQUES DE PROTÉINES KINASES C ATYPIQUES
  申请人：UNIV SAARLAND

  公开号：WO2015075051A1

  公开（公告）日：2015-05-28

  The invention provides specific small molecule compounds that allosterically regulate the activity of atypical protein kinase C, their use as a medicament, and their use in the treatment and prevention of allergic, inflammatory and autoimmune disorders, cancer, hyperproliferation, sepsis, viral and protozoan infections, dementing diseases, metabolic, sclerotic and osteoporotic disorders.

  这项发明提供了特定的小分子化合物，可以对非典型蛋白激酶C的活性进行变构调节，其用作药物，并用于治疗和预防过敏、炎症和自身免疫性疾病、癌症、过度增殖、败血症、病毒和原虫感染、痴呆症、代谢性疾病、硬化和骨质疏松症。
• [EN] NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER<br/>[FR] MODULATEURS DE RÉCEPTEURS NUCLÉAIRES ET LEUR UTILISATION POUR LE TRAITEMENT ET LA PRÉVENTION D'UN CANCER
  申请人：US HEALTH

  公开号：WO2012174436A1

  公开（公告）日：2012-12-20

  Disclosed are compounds which are nuclear receptor modulators that can act as antagonists to the androgen receptor, for example, a compound of Formula I: wherein R1 to R5 and X1 to X5 are as described herein, as well as pharmaceutically acceptable salts, solvates, and stereoisomers thereof. Pharmaceutical compositions comprising such compounds, as well as methods of use, and treatment for cancers, including prostate cancers, other nuclear receptor mediated cancers, and other conditions, are also disclosed.

  本文披露了一些化合物，它们是核受体调节剂，可以作为雄激素受体的拮抗剂，例如，公式I的化合物：其中R1至R5和X1至X5如本文所述，以及其药用盐、溶剂化合物和立体异构体。还披露了包括这些化合物的药物组合物，以及使用方法和治疗癌症，包括前列腺癌、其他核受体介导的癌症和其他疾病的方法。
• Design, synthesis, topoisomerase I &amp; II inhibitory activity, antiproliferative activity, and structure–activity relationship study of pyrazoline derivatives: An ATP-competitive human topoisomerase IIα catalytic inhibitor
  作者：Pervez Ahmad、Hyunjung Woo、Kyu-Yeon Jun、Adnan A. Kadi、Hatem A. Abdel-Aziz、Youngjoo Kwon、A.F.M. Motiur Rahman

  DOI：10.1016/j.bmc.2016.03.017

  日期：2016.4

  A series of pyrazoline derivatives (5) were synthesized in 92–96% yields from chalcones (3) and hydrazides (4). Subsequently, topo-I and IIα-mediated relaxation and antiproliferative activity assays were evaluated for 5. Among the tested compounds, 5h had a very strong topo-I activity of 97% (Camptothecin, 74%) at concentration of 100 μM. Nevertheless, all the compounds 5a–5i showed significant topo

  从查耳酮（3）和酰肼（4）合成了一系列吡唑啉衍生物（5），产率为92–96％。随后，对topo-I和IIα介导的舒张和抗增殖活性测定进行了评估5。在测试的化合物中，浓度为100μM的5h的topo-I活性非常强，为97％（喜树碱，74％）。尽管如此，所有化合物5a – 5i在相同浓度下显示出显着的topo II抑制活性，范围为90-94％（依托泊苷，96％）。在一组三种人类肿瘤细胞系HCT15，BT474和T47D中测试了这些化合物的细胞毒性潜力。所有化合物均在1.9-10.4μM的范围内显示出对HCT15细胞系的强活性，IC 50为（阿霉素23.0；依托泊苷6.9；喜树碱7.1μM）。此外，观察到化合物5c，5f和5i对BT474细胞系具有强的抗增殖活性。由于化合物5d在非常低的IC 50下显示出抗增殖活性，因此5d然后选择了ATP，通过多种ATP竞争测定，ATPase测定和DNA-to
• NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER
  申请人：The U.S.A. as represented by the Secretary, Department of Health and Human Services

  公开号：EP3333153A1

  公开（公告）日：2018-06-13

  Disclosed are compounds which are nuclear receptor modulators that can act as antagonists to the androgen receptor, for example, a compound of Formula I: wherein R1 to R5 and X1 to X5 are as described herein, as well as pharmaceutically acceptable salts, solvates, and stereoisomers thereof. Pharmaceutical compositions comprising such compounds, as well as methods of use, and treatment for cancers, including prostate cancers, other nuclear receptor mediated cancers, and other conditions, are also disclosed.

  所公开的化合物是核受体调节剂，可作为雄激素受体的拮抗剂，例如，式 I 的化合物： 其中 R1 至 R5 和 X1 至 X5 如本文所述，以及其药学上可接受的盐、溶剂和立体异构体。此外，还公开了包含此类化合物的药物组合物，以及使用方法和癌症（包括前列腺癌、其他核受体介导的癌症和其他疾病）的治疗方法。